Literature DB >> 24211331

Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Jeffrey D Meteer1, Raymond F Schinazi2, John W Mellors3, Nicolas Sluis-Cremer4.   

Abstract

We reported that 3'-azido-2',3'-dideoxyguanosine (3'-azido-ddG) selected for the L74V, F77L, and L214F mutations in the polymerase domain and K476N and V518I mutations in the RNase H domain of HIV-1 reverse transcriptase (RT). In this study, we have defined the molecular mechanisms of 3'-azido-ddG resistance by performing in-depth biochemical analyses of HIV-1 RT containing mutations L74V, F77L, V106I, L214F, R277K, and K476N (SGS3). The SGS3 HIV-1 RT was from a single-genome-derived full-length RT sequence obtained from 3'-azido-ddG resistant HIV-1 selected in vitro. We also analyzed two additional constructs that either lacked the L74V mutation (SGS3-L74V) or the K476N mutation (SGS3-K476N). Pre-steady-state kinetic experiments revealed that the L74V mutation allows RT to effectively discriminate between the natural nucleotide (dGTP) and 3'-azido-ddG-triphosphate (3'-azido-ddGTP). 3'-azido-ddGTP discrimination was primarily driven by a decrease in 3'-azido-ddGTP binding affinity (Kd) and not by a decreased rate of incorporation (kpol). The L74V mutation was found to severely impair RT's ability to excise the chain-terminating 3'-azido-ddG-monophosphate (3'-azido-ddGMP) moiety. However, the K476N mutation partially restored the enzyme's ability to excise 3'-azido-ddGMP on an RNA/DNA, but not on a DNA/DNA, template/primer by selectively decreasing the frequency of secondary RNase H cleavage events. Collectively, these data provide strong additional evidence that the nucleoside base structure is major determinant of HIV-1 resistance to the 3'-azido-2',3'-dideoxynucleosides.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3′-Azido-2′,3′-dideoxyguanosine; 3′-Azido-ddG; 3′-Azido-ddGMP; 3′-Azido-ddGTP; 3′-azido-2′,3′-dideoxyguanosine; 3′-azido-ddG-monophosphate; 3′-azido-ddG-triphosphate; 50% inhibitory concentration; AZT; DP; Discrimination; Excision; HIV-1; IC(50); MP; NRTI; NRTIs; RNase H; RT; Resistance; Reverse transcriptase; T/P; TP; WT; diphosphate; monophosphate; nucleoside RT inhibitor; nucleoside reverse transcriptase inhibitors; reverse transcriptase; ribonuclease H; template/primer; triphosphate; wild-type; zidovudine

Mesh:

Substances:

Year:  2013        PMID: 24211331      PMCID: PMC3889670          DOI: 10.1016/j.antiviral.2013.10.017

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  38 in total

1.  HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

Authors:  V Miller; M Ait-Khaled; C Stone; P Griffin; D Mesogiti; A Cutrell; R Harrigan; S Staszewski; C Katlama; G Pearce; M Tisdale
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

2.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

3.  Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

5.  Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates.

Authors:  P R Meyer; S E Matsuura; R F Schinazi; A G So; W A Scott
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity.

Authors:  Jason W Rausch; Daniela Lener; Jennifer T Miller; John G Julias; Stephen H Hughes; Stuart F J Le Grice
Journal:  Biochemistry       Date:  2002-04-16       Impact factor: 3.162

7.  Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity.

Authors:  John G Julias; Mary Jane McWilliams; Stefan G Sarafianos; W Gregory Alvord; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions.

Authors:  Jérôme Deval; Jean-Marc Navarro; Boulbaba Selmi; Jérôme Courcambeck; Joëlle Boretto; Philippe Halfon; Sarah Garrido-Urbani; Josephine Sire; Bruno Canard
Journal:  J Biol Chem       Date:  2004-03-23       Impact factor: 5.157

9.  The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues.

Authors:  Jerome Deval; Boulbaba Selmi; Joelle Boretto; Marie Pierre Egloff; Catherine Guerreiro; Simon Sarfati; Bruno Canard
Journal:  J Biol Chem       Date:  2002-08-22       Impact factor: 5.157

Review 10.  HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Authors:  Michele W Tang; Robert W Shafer
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

View more
  1 in total

1.  Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART.

Authors:  Ann Wiegand; Jonathan Spindler; Feiyu F Hong; Wei Shao; Joshua C Cyktor; Anthony R Cillo; Elias K Halvas; John M Coffin; John W Mellors; Mary F Kearney
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-17       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.